Despite its association with peripheral lymphopenia, and specifically CD4 + lymphopenia, the original landmark clinical trials demonstrated similar overall incidences of infection between participants treated with fingolimod, and control groups [21], [25]. This evidence concerns the gene CD4 and lymphopenia.